ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
ParticipantND
NAVER D2SF
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Sep 19, 2026
NAVER D2SF is NAVER’s startup investment organization, identified through official materials for ImpriMed and NdotLight.
Recorded funding activity
ImpriMed combines live-cell drug testing with clinical data. NdotLight generates simulation-ready 3D data, while F4GE structures factory information for industrial buyers. The organization retains its identity separately from NAVER Ventures and the parent.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $10M 1 disclosed · full round size, not this investor’s share